Assembly Biosciences (ASMB)
NASDAQ:ASMB
Want to see ASMB full AI Analyst Report?
Top Page
Assembly Biosciences
(NASDAQ:ASMB)
Select Model
Select Model
Rating:52Neutral
Price Target:
$30.00
▲(2.60% Upside)
Action:ReiteratedDate:05/10/26
The score is held back primarily by weak cash flow and ongoing unprofitability despite a strong, low-leverage balance sheet. Technicals are moderately positive with the stock above key moving averages, while valuation is constrained by losses (negative P/E) and no dividend yield data. A modestly positive corporate governance/compensation update provides limited incremental support.
Positive Factors
Balance sheet strength
A very low-debt capital structure and sizable equity base provide durable financial flexibility for a clinical-stage biotech. This reduces near-term insolvency risk, supports continued R&D spending or licensing deals without immediate forced dilution, and improves negotiating power with partners.
Negative Factors
Accelerating cash burn
Substantial negative operating and free cash flows, with sharply worsening FCF growth, indicate the company is consuming cash rapidly to fund development. Sustained burn will require external financing or partnerships, raising dilution and execution risk and constraining strategic optionality over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A very low-debt capital structure and sizable equity base provide durable financial flexibility for a clinical-stage biotech. This reduces near-term insolvency risk, supports continued R&D spending or licensing deals without immediate forced dilution, and improves negotiating power with partners.
Read all positive factors
Assembly Biosciences (ASMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$472.65M
Dividend YieldN/A
Average Volume (3M)164.41K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth121.11%
EPS Growth80.74%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding15,892,608
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue6.25
Enterprise Value/Gross Profit8.09
Enterprise Value/Ebitda-37.74
Forecast
1Y Price Target
$44.33Price Target Upside51.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$55.69M
Assembly Biosciences Business Overview & Revenue Model
Company Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, whic...
How the Company Makes Money
null...
Assembly Biosciences Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 71.10M | 72.30M | 28.52M | 7.16M | 0.00 | 6.25M |
| Gross Profit | 54.91M | 72.17M | 28.52M | -41.74M | -69.08M | 6.25M |
| EBITDA | -11.76M | -11.99M | -45.29M | -64.20M | -92.52M | -90.58M |
| Net Income | -6.38M | -6.12M | -40.18M | -61.23M | -93.09M | -129.85M |
Balance Sheet | ||||||
| Total Assets | 235.51M | 257.59M | 119.17M | 136.82M | 101.79M | 191.06M |
| Cash, Cash Equivalents and Short-Term Investments | 226.60M | 248.11M | 112.08M | 130.25M | 91.61M | 146.63M |
| Total Debt | 2.49M | 2.63M | 3.09M | 2.34M | 3.46M | 6.48M |
| Total Liabilities | 36.90M | 50.84M | 85.81M | 95.73M | 19.13M | 22.13M |
| Stockholders Equity | 198.61M | 206.75M | 33.36M | 41.10M | 82.66M | 168.93M |
Cash Flow | ||||||
| Free Cash Flow | -39.84M | -41.16M | -51.15M | 22.49M | -84.56M | -96.49M |
| Operating Cash Flow | -39.75M | -41.09M | -51.12M | 22.74M | -84.46M | -93.40M |
| Investing Cash Flow | -125.44M | -113.47M | 40.17M | -69.14M | 90.64M | 26.52M |
| Financing Cash Flow | 172.89M | 174.67M | 29.45M | 13.82M | 614.00K | 53.06M |
Assembly Biosciences Technical Analysis
Positive
29.24
Price Trends
28.45
Positive
30.36
Negative
27.69
Positive
Market Momentum
0.25
Negative
52.21
Neutral
51.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Positive. The current price of 29.24 is above the 20-day moving average (MA) of 28.79, above the 50-day MA of 28.45, and above the 200-day MA of 27.69, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 52.21 is Neutral, neither overbought nor oversold. The STOCH value of 51.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASMB.
Assembly Biosciences Risk Analysis
Assembly Biosciences disclosed 29 risk factors in its most recent earnings report. Assembly Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Assembly Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $421.87M | -13.08 | -38.92% | ― | ― | 68.74% | |
52 Neutral | $472.65M | -12.91 | -5.63% | ― | 121.11% | 80.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $196.16M | -1.93 | -47.35% | ― | -46.21% | 23.81% | |
48 Neutral | $431.93M | -9.06 | -67.33% | ― | ― | 29.16% | |
47 Neutral | $924.67M | -6.09 | -101.19% | ― | ― | -3.74% | |
47 Neutral | $827.48M | 0.02 | 72.70% | ― | ― | -880.05% |
* Healthcare Sector Average
ASMB
Assembly Biosciences
29.74
17.39
140.81%
BNTC
Benitec Biopharma
12.28
-0.86
-6.54%
ANNX
Annexon Biosciences
5.69
3.92
221.47%
QSI
Quantum-Si
0.91
-0.60
-40.00%
VOR
Vor Biopharma
16.94
13.49
391.01%
LXEO
Lexeo Therapeutics, Inc.
5.83
3.20
121.67%
Assembly Biosciences Corporate Events
Business Operations and StrategyExecutive/Board Changes
Assembly Biosciences Adopts 2026 Performance-Based Bonus Plan
Positive
Mar 30, 2026
On March 24, 2026, Assembly Biosciences’ board compensation committee approved a new 2026 Corporate Bonus Plan, effective January 1, 2026, establishing a performance-based cash incentive structure for employees based on a mix of company-wide...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.